NPM1 and acute myeloid leukemia: On further analyses of survival in the patients with ELN2022 favorable risk (NPM1MT without and cytogenetically normal AML (CN-AML)), the OS benefit of NPM1 mutation was still restricted to the ≤65-year age group (NE vs. 38 mo., p = 0.001) and did not extend to the >65-year group (12 mo.